What is Oncodesign Precision Medicine?
Founded in 1995, Oncodesign Precision Medicine operates at the intersection of scientific innovation and pharmaceutical manufacturing. The company provides a comprehensive suite of integrated drug discovery services, including metabolism studies, pharmacokinetics, and biosafety protocols. Its core competency lies in the development of kinase inhibitors, a therapeutic class that remains central to modern oncology and inflammatory disease treatment strategies.
Beyond its internal research programs, the company functions as a vital partner in the biopharmaceutical ecosystem, offering biobanking and translational services that bridge the gap between laboratory discovery and clinical application. By maintaining a robust technological infrastructure, Oncodesign enables its partners to streamline the development of drug candidates, thereby reducing the time-to-market for precision medicine therapies.
How much funding has Oncodesign Precision Medicine raised?
Oncodesign Precision Medicine has raised a total of $6.3M across 1 funding round:
Other Financing Round
$6.3M
Other Financing Round (2023): $6.3M with participation from Crédit Agricole, Caisse d'Epargne, and Societe Generale
Key Investors in Oncodesign Precision Medicine
Crédit Agricole
A leading French banking and financial services group that has evolved into one of Europe's largest universal banks, providing a full spectrum of corporate and investment banking services.
Caisse d'Epargne
A historic French semi-cooperative bank founded in 1818, specializing in comprehensive retail and private banking solutions for a diverse client base.
Societe Generale
A prominent French-based multinational financial services company offering extensive expertise in retail banking, private banking, and insurance sectors.
What's next for Oncodesign Precision Medicine?
With the successful closure of this funding round, Oncodesign Precision Medicine is positioned to intensify its focus on high-growth therapeutic areas. The strategic deployment of these funds will likely prioritize the expansion of its kinase inhibitor programs and the enhancement of its translational research capabilities. By leveraging its established partnerships and deep scientific expertise, the company is well-equipped to address the evolving demands of the precision medicine market.
Looking ahead, the firm is expected to continue its trajectory of technological integration, potentially exploring new frontiers in fibrosis drug development and advanced diagnostic tools. This financial backing provides the necessary runway to sustain long-term R&D initiatives, ensuring that Oncodesign remains a pivotal player in the global effort to deliver targeted, patient-centric healthcare outcomes.
